Straits Times Index
3,287.75 -5.38 (-0.16%) S&P 500
5,043.00 -28.63 (-0.56%) Dow
38,099.46 -361.46 (-0.94%) Nasdaq
15,578.74 -134.01 (-0.85%) Bitcoin USD
64,556.05 -471.72 (-0.73%) CMC Crypto 200
1,391.58 +9.00 (+0.65%)
Teva Pharmaceutical Industries Limited (TEVA)
| Previous close | 13.01 |
| Open | 12.81 |
| Bid | 13.10 x 1800 |
| Ask | 13.11 x 2200 |
| Day's range | 12.80 - 13.14 |
| 52-week range | 7.09 - 14.47 |
| Volume | |
| Avg. volume | 10,092,380 |
| Market cap | 14.866B |
| Beta (5Y monthly) | 1.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 27 Nov 2017 |
| 1y target est | N/A |
- Business Wire
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
REYKJAVIK, Iceland & PARSIPPANY, N.J., April 16, 2024--Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. Under
- Business Wire
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
TEL AVIV, Israel & PARSIPPANY, N.J., April 16, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced final results from the HD cohort of the Phase 4 START study, demonstrating positive real-world effectiveness, safety, adherence and satisfaction with the 4-week Titration Kit for AUSTEDO. As a fatal, neurodegenerative disease, HD can cause cognitive deterioration, behavioral and/or psychological problems and uncontrollable body
- Business Wire
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
TEL AVIV, Israel & PARSIPPANY, N.J., April 11, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a Phase 3 study evaluating the efficacy and safety of AJOVY for the prevention of migraine in adult Chinese patients.
